Site-directed M2 proton channel inhibitors enable synergistic combination therapy for rimantadine-resistant pandemic influenza

Scott, C, Kankanala, J, Foster, TL et al. (20 more authors) (2020) Site-directed M2 proton channel inhibitors enable synergistic combination therapy for rimantadine-resistant pandemic influenza. PLOS Pathogens, 16 (8). e1008716. ISSN 1553-7366

Abstract

Metadata

Authors/Creators:
Copyright, Publisher and Additional Information: © 2020 Scott et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Dates:
  • Accepted: 19 June 2020
  • Published (online): 11 August 2020
  • Published: 11 August 2020
Institution: The University of Leeds
Academic Units: The University of Leeds > Faculty of Engineering & Physical Sciences (Leeds) > School of Physics and Astronomy (Leeds) > Soft Matter Physics (Leeds)
The University of Leeds > Faculty of Medicine and Health (Leeds) > School of Medicine (Leeds) > Leeds Institute of Cardiovascular and Metabolic Medicine (LICAMM) > Discovery & Translational Science Dept (Leeds)
Funding Information:
FunderGrant number
MRC (Medical Research Council)G0700124 ID 81396
PfizerFELLOWSHIP S. GRIFFIN
PfizerNOT GIVEN
Depositing User: Symplectic Publications
Date Deposited: 20 Aug 2020 15:06
Last Modified: 20 Aug 2020 15:06
Status: Published
Publisher: Public Library of Science
Identification Number: https://doi.org/10.1371/journal.ppat.1008716
Related URLs:

Share / Export

Statistics